Sunday, 19th November 2017
Senegal
France
Germany
The Netherlands
United Kingdom

Work package 4

Ebola viral dynamics in vivo and the antiviral efficacy of Favipiravir: from small animals to human clinical trial.

The main objective of this workpackage is the analysis of the data from WP1 (humans) and WP3 (non-human primates) to provide a quantitative understanding of the determinants of the viro-immunologic response to treatment.

Involved institutions
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France):
Prof. Jeremie Guedj (WP lead), Prof. France Mentré

BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (Germany):
Prof. Stephan Günther

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG (Germany) :
Dr. Frederik Graw

UNIVERSITEIT UTRECHT (The Netherlands):
Prof. Rob de Boer